The physiology and pharmacology of incretins in type 2 diabetes mellitus

Diabetes, Obesity and Metabolism

Volumn 10, Issue SUPPL. 3, 2008, Pages 14-21

  Holst, Jens J ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Incretins; Pharmacology; Physiology; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 AGONIST; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCOSE; INCRETIN; INSULIN; LIRAGLUTIDE; PLACEBO;

CLINICAL TRIAL; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG MECHANISM; DRUG SCREENING; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HORMONE ACTION; HORMONE METABOLISM; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; STOMACH EMPTYING; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

EID: 47649086665     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00920.x     Document Type: Review

References (44)

1. Moore B. On the treatment of diabetes mellitus by acid extract of duodenal mucous membrane. Biochem J 1906; 1: 28-38.
2. Nauck MA. GLP-1 in type 2 diabetes: The β-cell and beyond. Diabetes Obes Metab 2008; 10 (Suppl. 3): 2-13.
3. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26: 2929-2940.
4. Nauck MA, Homberger E, Siegel EG et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986; 63: 492-498.
5. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46-52.
6. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 1409-1439.
7. Ørskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans. Diabetes 1994; 43: 535-539.
8. Mortensen K, Christensen LL, Holst JJ, Ørskov C. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Pept 2003; 114: 189-196.
9. Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 2000; 85: 3575-3581.
10. Mentlein R, Gallwitz B, Schmidt WE et al. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993; 214: 829-835.
11. Hansen L, Deacon CF, Ørskov C, Holst JJ. Glucagon-like peptide-1 (7-36)amide is transformed to glucagon-like peptide-1 (9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L-cells of the porcine intestine. Endocrinology 1999; 140: 5356-5363.
12. Ørskov C, Wettergren A, Holst JJ. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol 1996; 31: 665-670.
13. Herrmann C, Göke R, Richter G, Fehmann HC, Arnold R, Göke B. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 1995; 56: 117-126.
14. Deacon CF. What do we know about the secretion and degradation of incretin hormones? Regul Pept 2005; 128: 117-124.
15. Anini Y, Brubaker PL. Muscarinic receptors control glucagon-like peptide 1 secretion by human endocrine L cells. Endocrinology 2003; 144: 3244-3250.
16. Hansen L, Hartmann B, Bisgaard T, Mineo H, Jørgensen PH, Holst JJ. Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. Am J Physiol Endocrinol Metab 2000; 278: E1010-E1018.
17. Herrmann-Rinke C, Vöge A, Hess M, Göke B. Regulation of glucagon-like peptide-1 secretion from rat ileum by neurotransmitters and peptides. J Endocrinol 1995; 147: 25-31.
18. Hansen L, Holst JJ. The effects of duodenal peptides on glucagon-like peptide-1 secretion from the ileum. A duodeno-ileal loop? Regul Pept 2002; 110: 39-45.
19. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91: 301-307.
20. Mayo KE, Miller JL, Bataille D et al. International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev 2003; 55: 167-194.
21. Holz GG. Epac: A new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell. Diabetes 2004; 53: 5-13.
22. Holst JJ, Ørskov C, Nielsen OV, Schwartz TW. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett 1987; 211: 169-174.
23. Mojsov S, Weir GC, Habener JF. Insulinotropin: Glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 1987; 79: 616-619.
24. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: A physiological incretin in man. Lancet 1987; ii: 1300-1304.
25. Ørskov C, Holst JJ, Nielsen OV. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 1988; 123: 2009-2013.
26. Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 2007; 113: 546-593.
27. Drucker DJ. The biology of the incretins. Cell Metab 2006; 3: 153-165.
28. Nauck MA, Niedereichholz U, Etter R et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy volunteers. Am J Physiol 1997; 273: E981-E988.
29. Meier JJ, Kemmeries G, Holst JJ, Nauck MA. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes 2005; 54: 2212-2218.
30. Gros R, You X, Baggio CC et al. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 2003; 144: 2242-2252.
31. Nikolaidis LA, Elahi D, Hentosz T et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004; 110: 955-961.
32. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005; 54: 146-151.
33. Turton MD, O'Shea D, Gunn I et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996; 379: 69-72.
34. Tang-Christensen M, Larsen PH, Göke R et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 1996; 271: R848-R856.
35. Meeran K, O'Shea D, Edwards CM et al. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology 1999; 140: 244-250.
36. Muscelli E, Mari A, Casolaro A et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008; 57: 1340-1348.
37. Toft-Nielsen MB, Damholt MB, Madsbad S et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86: 3717-3723.
38. Kjems LL, Holst JJ, Vølund A, Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: Effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003; 52: 380-386.
39. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creuzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 741-744.
40. Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 2002; 45: 1111-1119.
41. Knop FK, Vilsbøll T, Højberg PV et al. Reduced incretin effect in type 2 diabetes: Cause or consequence of the diabetic state? Diabetes 2007; 56: 1951-1959.
42. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study. Lancet 2002; 359: 824-880.
43. Holz GG IV, Kühtreiber WM, Habener JF. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1 (7-37). Nature 1993; 361: 362-365.
44. Garber A. GLP-1-based therapies: New developments and emerging data. Diabetes Obes Metab 2008; 10 (Suppl. 3): 22-35.